– RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly ...
Session: Session 9: Targeting Non-malignant DiseasesTitle: Clinical and Translational Studies of Rese-cel (an anti-CD19 CAR T Therapy) in Myositis, SLE, and Systemic Sclerosis: RESET Phase I/II ...
Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results